Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Related TEVA
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Jana Partners LLC Files its 13F
Sofinnova Ventures Closes $500M Fund (Fox Business)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters